Moleculin Biotech faces critical funding test as Annamycin’s 43% leukemia remission rate advances toward pivotal readout
PulseAI wins FDA clearance for smartwatch ECG analysis after study shows 92% fewer inconclusive results
Read More Healthcare Industry News GRAIL stock surges 14% after $110m Samsung deal to expand Galleri test in Asia GRAIL stock jumps 14% after Samsung's $110M investment and Asia commercialization deal for its Galleri cancer test. Learn how investors are reacting. byVenkateshOctober 16, 2025